The stock of PTC Therapeutics, Inc. (NASDAQ:PTCT) is a huge mover today! About 1.75M shares traded hands. PTC Therapeutics, Inc. (NASDAQ:PTCT) has declined 38.29% since April 4, 2016 and is downtrending. It has underperformed by 39.38% the S&P500.
The move comes after 6 months positive chart setup for the $169.58M company. It was reported on Nov, 4 by Barchart.com. We have $14.02 PT which if reached, will make NASDAQ:PTCT worth $313.72 million more.
Analysts await PTC Therapeutics, Inc. (NASDAQ:PTCT) to report earnings on November, 14. They expect $-1.19 EPS, up 6.30% or $0.08 from last year’s $-1.27 per share. After $-1.14 actual EPS reported by PTC Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 4.39% negative EPS growth.
PTC Therapeutics, Inc. (NASDAQ:PTCT) Ratings Coverage
Out of 7 analysts covering PTC Therapeutics (NASDAQ:PTCT), 2 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 29% are positive. PTC Therapeutics has been the topic of 16 analyst reports since July 31, 2015 according to StockzIntelligence Inc. The company was maintained on Wednesday, February 24 by Wedbush. On Wednesday, January 20 the stock rating was initiated by Credit Suisse with “Outperform”. The firm earned “Outperform” rating on Thursday, February 25 by Oppenheimer. The firm earned “Hold” rating on Friday, October 23 by Jefferies. RBC Capital Markets maintained the shares of PTCT in a report on Friday, July 31 with “Outperform” rating. The stock of PTC Therapeutics, Inc. (NASDAQ:PTCT) has “Buy” rating given on Tuesday, August 25 by Citigroup. As per Wednesday, February 24, the company rating was downgraded by Citigroup. The firm earned “Outperform” rating on Friday, October 16 by Oppenheimer. The firm has “Underperform” rating given on Wednesday, November 25 by Jefferies. RBC Capital Markets maintained the stock with “Outperform” rating in Friday, October 16 report.
According to Zacks Investment Research, “PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of orally administered, small-molecule drugs for genetic disorders, oncology and infectious disease. PTC Therapeutics, Inc. is based in South Plainfield, United States.”
Insitutional Activity: The institutional sentiment increased to 1.23 in 2016 Q2. Its up 0.40, from 0.83 in 2016Q1. The ratio increased, as 17 funds sold all PTC Therapeutics, Inc. shares owned while 30 reduced positions. 17 funds bought stakes while 41 increased positions. They now own 28.13 million shares or 3.23% less from 29.06 million shares in 2016Q1.
Oppenheimer And Com last reported 0.02% of its portfolio in the stock. Stonebridge Capital Mngmt owns 21,385 shares or 0.07% of their US portfolio. Nationwide Fund Advsr last reported 35,300 shares in the company. Swiss National Bank has 0% invested in the company for 50,065 shares. Blackrock Fund Advisors last reported 1.30 million shares in the company. Teacher Retirement Sys Of Texas has 4,250 shares for 0% of their US portfolio. Frontier Mngmt Com Ltd Liability Corporation has 0.08% invested in the company for 1.43M shares. Parametric Assoc Lc accumulated 0% or 53,184 shares. Qs Ltd has invested 0.01% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT). Moreover, Metropolitan Life Ins Ny has 0% invested in PTC Therapeutics, Inc. (NASDAQ:PTCT) for 23,703 shares. Jennison Assocs has invested 0% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT). Financial Bank Of America De has 0% invested in the company for 503,119 shares. Camber Cap Management Ltd Com last reported 1.50M shares in the company. Jpmorgan Chase And Company holds 345,941 shares or 0% of its portfolio. Northern Corp has 456,607 shares for 0% of their US portfolio.
More notable recent PTC Therapeutics, Inc. (NASDAQ:PTCT) news were published by: Foxbusiness.com which released: “Here’s Why PTC Therapeutics, Inc. Is Crashing Today” on November 03, 2016, also Fool.com with their article: “Why PTC Therapeutics, Inc. Is Crashing Today” published on October 17, 2016, Marketwatch.com published: “PTC Therapeutics stock plummets 29% after FDA denies company’s DMD drug appeal” on October 17, 2016. More interesting news about PTC Therapeutics, Inc. (NASDAQ:PTCT) were released by: Reuters.com and their article: “BRIEF-PTC Therapeutics says total revenue for Q3 2016 was $23 mln” published on November 02, 2016 as well as Prnewswire.com‘s news article titled: “PTC Therapeutics to Host Conference Call to Discuss Third Quarter Financial …” with publication date: October 19, 2016.
PTCT Company Profile
PTC Therapeutics, Inc., incorporated on March 31, 1998, is a biopharmaceutical firm focused on the discovery, development and commercialization of orally administered, small molecule therapeutics that focus on post-transcriptional control processes. The Company’s internally discovered pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases. The Company’s lead product, Translarna (ataluren), is used for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients with age of over five years and older in over 30 member states of the European Economic Area (EEA). It holds commercialization rights to Translarna for all indications in all territories, across the world. Translarna is designated as an orphan medicinal product for the treatment of cystic fibrosis (CF), duchenne muscular dystrophy (DMD), Mucopolysaccharidosis type I (MPS I), and aniridia. The Company’s programs include Translarna for nmDMD, Translarna for nonsense mutation cystic fibrosis (nmCF), Translarna for mucopolysaccharidosis type I caused by nonsense mutation (nmMPS I), Translarna for nonsense mutation aniridia, Translarna for nonsense mutation Dravet syndrome/CDKL5, Spinal muscular atrophy (SMA) collaboration with Spinal Muscular Atrophy Foundation (SMA Foundation) and F. Hoffman-La Roche Ltd and Hoffman- La Roche Inc. (collectively Roche), and Cancer stem cell program (PTC596).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.